2017
New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li X, Oprea-Ilies G, Krishnamurti U. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives Of Pathology & Laboratory Medicine 2017, 141: 490-498. PMID: 28353377, DOI: 10.5858/arpa.2016-0288-sa.Peer-Reviewed Original ResearchConceptsBreast cancerDaily practiceBreast specimensTriple-negative breast cancerDistinct biological subsetsHER2/neu gene amplificationTumor-infiltrating lymphocytesRadioactive seed localizationAppropriate treatment groupsNovel clinical practicesNeu gene amplificationNeoadjuvant treatmentPathologic evaluationHistopathologic parametersTreatment groupsClinical practiceTherapeutic utilityBiological subsetsCancerMolecular classificationBest treatmentPathologyNew guidelinesSeed localizationGene amplification
2016
A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.
Bhattarai S, Xia J, Sonmez Wetherilt C, Pattni S, Klimov S, Riaz A, Aleskandarany M, Green A, Rakha E, Ellis I, Cantuaria G, Li X, Krishnamurti U, Osan R, Rida P, Aneja R. A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers. Journal Of Clinical Oncology 2016, 34: 1089-1089. DOI: 10.1200/jco.2016.34.15_suppl.1089.Peer-Reviewed Original Research
2014
HER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapyThe Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma
Krishnamurti U, Silverman J. The Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma. Advances In Anatomic Pathology 2014, 19: 13-17. DOI: 10.1097/pcr.0000000000000016.Peer-Reviewed Original ResearchAdverse prognostic factorHER2 amplificationBreast cancerPrognostic factorsHuman epidermal growth factor receptor 2 (HER2) oncoproteinCopy number alterationsInvasive breast cancerInvasive breast carcinomaHER2/CEP17HER2 gene amplificationNumber alterationsHER2 copy numberChromosome 17 polysomyCEP17 duplicationMost patientsHER2 overexpressionBreast carcinomaClinicopathologic significanceHER2 2Chromosome 17PatientsCancerProtein overexpressionCopy numberHER2